A Systematix Research report said India's pharma industry needs price hikes, site and IP transfers to manage US tariff uncertainty. While raw material prices, especially antibiotics, are correcting and API prices have stabilised, US generics face margin pressure. Firms eye GLP-1 opportunities and CDMO growth, but weak 1QFY26 earnings highlight sectoral challenges.